Advertisements


Alnylam says Onpattro to be available from two specialty pharmacies

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 10th, 2018

Alnylam & Medison Partner to Market RNAi Products in Israel

Alnylam (ALNY) partners with Israel's Medison Pharma to commercialize Onpattro and other RNAi pipeline candidates und.....»»

Category: worldSource: nytJan 22nd, 2019

Alnylam, Israel"s Medison partner to commercialize Onpattro, RNAi portfolio

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 21st, 2019

Alnylam Reports Improved Onpattro Sales Going Into A Busy Year

Alnylam Reports Improved Onpattro Sales Going Into A Busy Year.....»»

Category: topSource: seekingalphaJan 8th, 2019

Alnylam (ALNY) Reports Preliminary Onpattro Revenues for Q4

Alnylam (ALNY) reports preliminary revenues for Onpattro for the fourth quarter of 2018, and also provides other update.....»»

Category: personnelSource: nytJan 8th, 2019

Alnylam reports better-than-expected Onpattro revenues, says Piper Jaffray

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 7th, 2019

Alnylam announces unaudited Q4 ONPATTRO revenues of $11M-$12M

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 7th, 2019

A Sluggish Start With Onpattro Is Not What Alnylam Shareholders Needed

A Sluggish Start With Onpattro Is Not What Alnylam Shareholders Needed.....»»

Category: topSource: seekingalphaNov 20th, 2018

Alnylam"s Onpattro highly efficacious, safer than competitor, says Piper Jaffray

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 7th, 2018

Alnylam launches ONPATTRO in Germany

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 2nd, 2018

Alnylam announces submission of NDA in Japan for ONPATTRO

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 28th, 2018

Alnylam data publication points to positive Onpattro risk profile, says Cowen

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 14th, 2018

Alnylam"s Shares Up as Onpattro Gets FDA and EU Approvals

Zacks.....»»

Category: topSource: redinewsSep 5th, 2018

Alnylam receives approval of ONPATTRO in Europe

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 30th, 2018

JMP says Pfizer data "impressive," but leave room for Alnylam"s Onpattro

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 28th, 2018

Ionis CRL positive for Alnylam"s Onpattro, says B. Riley FBR

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 28th, 2018

Alnylam Pharmaceutical"s (ALNY) Conference Call to Discuss FDA Approval of ONPATTRO (Patisiran) - Slideshow

Alnylam Pharmaceutical"s (ALNY) Conference Call to Discuss FDA Approval of ONPATTRO (Patisiran) - Slideshow.....»»

Category: topSource: seekingalphaAug 13th, 2018

Alnylam (ALNY) Gets FDA Nod for First-Ever RNAi Therapeutic

Alnylam (ALNY) receives FDA approval for Onpattro to treat polyneuropathy of hereditary transthy.....»»

Category: dealsSource: nytAug 13th, 2018

Alnylam rare drug gets FDA approval, to cost $345,000 on average

Alnylam Pharmaceuticals Inc.'s rare disease drug Onpattro has been approved by the Food and Drug Administration, marking the first approval of a therapy that employs the RNA interference (RNAi) gene-silencing technique. Onpattro, also called patis.....»»

Category: topSource: marketwatchAug 11th, 2018

Alnylam rare drug gets FDA approval, to cost $345,000 on oaverage

Alnylam Pharmaceuticals Inc.'s rare disease drug Onpattro has been approved by the Food and Drug Administration, marking the first approval of a therapy that employs the RNA interference (RNAi) gene-silencing technique. Onpattro, also called patis.....»»

Category: topSource: marketwatchAug 10th, 2018

Alnylam expects Germany to be first EU launch country for Onpattro

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 10th, 2018